The Cooper Companies, Inc.
Rank #335HypergrowthCOO · Nasdaq · Healthcare
The Cooper Companies, Inc. (COO) — Rank #335 by gross profitability (GP/assets 0.21) · ROE 4.5% · Piotroski F-Score 5 / 9.
As-of 2026-09-15 · CIK 0000711404 · all metrics point-in-time as of the filing date.
About
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers.
Show moreShow less
The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc.
was founded in 1958 and is headquartered in San Ramon, California.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- October 31
- Website
- coopercos.com
Financials
Stable
Direction over 5 fiscal years
- Free cash flowstable
- Gross marginstable
- Gross profitabilitydeteriorating
- Net cashdeteriorating
- Operating marginstable
- Return on equityimproving
- Share count (dilution)deteriorating
Monitoring diagnostic of business direction — not a prediction of returns.
Each fiscal year is read as-of that year’s own 10-K filing, so nothing restated after the fact leaks backwards. Line items this filer never tagged are omitted. Hover or tap a badge for the diagnostic behind it.
| Fiscal year end | 2022-10-31filed 2022-12-09 | 2021-10-31filed 2021-12-10 | 2020-10-31filed 2020-12-11 | 2019-10-31filed 2019-12-20 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | 3,308.4 | 2,922.5 | 2,430.9 | 2,653.4 |
| Revenue growth (YoY) | 54.7% | 36.6% | 13.6% | 24.0% |
| Gross profit | 2,139.6 | 1,955.8 | 1,534.8 | 1,756.8 |
| Gross margin | 64.7% | 66.9% | 63.1% | 66.2% |
| Net income | 385.8 | 2,944.7 | 238.4 | 466.7 |
| Net margin | 11.7% | 100.8% | 9.8% | 17.6% |
| EPS (diluted) | $7.76 | $59.16 | $4.81 | $9.33 |
| EPS growth (YoY) | -86.9% | 1129.9% | -48.4% | — |
| Cash flow | ||||
| Operating cash flow | 692.4 | 738.6 | 486.6 | 713.2 |
| Capital expenditures | 242.0 | 214.4 | 310.4 | 292.1 |
| Free cash flow | 450.4 | 524.2 | 176.2 | 421.1 |
Figures are as originally filed with the SEC (point-in-time), not restated, so they can differ slightly from sites that show later-restated numbers. Why point-in-time?